RxDoctor Payments Data

Piyush Johari, MD

Psychiatry · West Springfield, MANPI 1053379016

Payments from drug & device makers

$3,239in general payments, 2019–2025

Across 166 payments — averaging $19.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$629
  • Otsuka America Pharmaceutical, Inc.$585
  • Johnson & Johnson$571
  • Neurocrine Biosciences, Inc.$305
  • Lundbeck LLC$225
  • Vanda Pharmaceuticals Inc.$212
  • plus $712 from 10 others

What the payments were for

  • Food & beverage$3,03094%
  • Education$2096%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,239 in reported general payments places this provider in the 85th percentile of 1,431 psychiatry providers in Massachusetts.

See all psychiatry providers in Massachusetts

Medicare billing

Part B allowed, 2024
$220,234
Medicare patients
177
Services billed
1,702

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl135$163,743
Austedo XrDeutetrabenazine12$71,800
NuplazidPimavanserin Tartrate13$66,194
VraylarCariprazine Hcl18$27,380
Vilazodone Hcl38$6,392
Duloxetine Hcl209$5,288
Lurasidone Hcl14$4,554
Desvenlafaxine Succinate ErDesvenlafaxine Succinate62$3,576
Bupropion XlBupropion Hcl136$3,463
Ziprasidone Hcl11$3,316
Quetiapine Fumarate138$2,876
Lorazepam430$2,635
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine29$2,065
Aripiprazole44$2,015
Donepezil Hcl37$1,855

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$571$163,743135 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$116$71,80012 claims
Acadia Pharmaceuticals IncNuplazid$73$66,19413 claims
AbbVieVraylar$629$27,38018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,431 psychiatry providers in Massachusetts.

Other psychiatry in West Springfield

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →